ID	CONTACT AUTHOR	TITLE	THEME	TOPIC	AREA
Euro16A-POS0003	Dr von Korn Hubertus	Interventional therapy of bifurcation lesions: a new approach using DEB for the main branch and/or for the side branch the DEBIFU registry (drug-eluting balloons for the treatment of bifurcation lesions)	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0004	Dr Tröbs Monique	Predictors of technical failure in transradial coronary angiography and intervention	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0011	Dr Dan Kazuhiro	Impact of combination of chronic kidney disease and c-reactive protein on cardiovascular events in patients undergoing PCI with DES	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0012	Dr LANDES Uri	Long-term PCI outcomes in cancer survivors	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0019	Dr Röther Jens	Comparison of low and high dose intracoronary adenosine for the measurement of coronary FFR	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0020	Dr Röther Jens	Clinical outcome of patients with "hybrid interventions" using both bioresorbable scaffolds and metal stents	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0021	Dr Kim Gwangsil	Predictors of poor clinical outcomes after successful CTO intervention with DES	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0026	Dr Sadamatsu Kenji	The X-ray dose reduction with fluoroscopy at 7.5 frames per second during coronary intervention	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0030	Dr MIZUGUCHI Yukio	Effect of coronary thebesian system on myocardial ischemia assessed based on coronary FFR	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0031	Dr MIZUGUCHI Yukio	Safety and efficacy of manual aspiration thrombectomy combined with transradial coronary intervention in the patients with ST-segment elevation myocardial infarction	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0042	Dr GUTIÉRREZ-BARRIOS Alejandro	Invasive assessment of coronary microvascular dysfunction in severe aortic stenosis	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0055	Mr Kherad Behrouz	PCI of the side branch using drug coated balloon vs. conventional balloon for provisional T-stenting of distal left main bifurcation stenosis	**Coronary Interventions**	Left main and MVD/ Bifurcation	Level 2 Zone D
Euro16A-POS0056	Dr Fu Qiang	High neutrophil-to-lymphocyte ratio may predict insufficient coronary reperfusion in patients with STEMI undergoing primary PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0057	Dr MASHAYEKHI Kambis	Comparison of the ipsilateral vs. contralateral retrograde approach of PCI in CTO	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0060	Dr Robaei Daniel	Two year outcomes of an everolimus-eluting BRS in real-world coronary artery disease	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0062	Dr FUKUZAWA Shigeru	Clinical assessment of myocardial perfusion imaging for the patients with insufficient FFR after DES implantation	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H

Euro16A-POS0081	Ms Cano-García Macarena	Use of mother-and-child catheter in complex PCI by radial access	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0082	Dr MBOUP Mouhamed Cherif	Difficulties of coronary angioplasty in a low income sub-saharan country	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0084	Ms Cano-García Macarena	Relationship between FFR and quantitative coronary angiography parameters in intermediate coronary artery stenosis	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0094	Dr Giordana Francesca	Provisional vs. two-stent technique for unprotected left main coronary artery disease after 10 years follow-up: a propensity matched analysis	**Coronary Interventions**	Left main and MVD/ Bifurcation	Level 2 Zone D
Euro16A-POS0095	Mr TAKAISHI Atsushi	The examination about the usefulness of the malondialdehyde-modified low-density lipoprotein (MDA-LDL) measurement in patients performed PCI for prediction of therapeutic effect and clinical prognosis in chronic stage	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0096	Prof Wang Lei	Protective effect of ticagrelor vs. clopidogrel against type 2 diabetes-induced vascular damage: a pilot study	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0103	Dr BUZURA Victor	DEB coronary angioplasty without stenting for De Novo lesions in very small-caliber vessels	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0111	Dr Slhessarenko Juliano	Effect of preloading with high-dose of rosuvastatin on levels of nitric oxide and C-reactive protein after PCI with metallic stents	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0112	Mr TAKAISHI Atsushi	The investigation about the reason of prognostic improvement in elderly patients received successful PCI in second generation DES era	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0115	Dr Rao Usha	Clinical outcomes of unprotected left main stem PCI in a non-surgical centre	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0123	Dr Moura-Ferreira Sara	In-hospital adverse outcome predictors of coronary stenting in unprotected left main coronary artery: a single-centre experience	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0127	Dr Kochergin Nikita	30-day follow-up of hybrid coronary revascularisation for multivessel coronary artery disease amongst patients with stable coronary artery disease	Coronary Interventions	Stable CAD/ Left main and MVD	Level 3 Zone I
Euro16A-POS0128	Dr Moncalvo Cinzia	Old SVG with important degeneration treated with self-expandable DES: our experience	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0131	Dr COHEN Avshalom	STEMI due to stent thrombosis and pain to door time: a beneficial association	**Coronary Interventions**	STEMI/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS0133	Mr Park Ha-Wook	Long-term residual risk according to optimal medical treatment in acute myocardial infarction treate with PCI: from the cohort in KAMIR-NIH	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0137	Dr Moon Donggyu	Five-year clinical outcome of high dose statin in patients with acute myocardial infarction in Asian according to age and left ventricular systolic function	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0149	Dr Azzalini Lorenzo	CTO in an all-comer patient population: incidence, decision-making and likelihood of revascularisation	**Coronary Interventions**	CTO	Level 2 Zone D

Euro16A-POS0153	Prof Han Seung Hwan	Real-world treatment and its long-term clinical outcomes between DES and CABG in patients with left main disease: a single-centre experience	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0155	Prof Han Seung Hwan	Clinical outcomes of multivessel coronary artery spasm are comparable to single vessel spasm on recommended optimal medical treatments: Korea vasospastic angina registry data analysis	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0159	Dr De la Torre Hernandez Jose Maria	Antithrombotic therapy during rescue angioplasty after failed fibrinolysis: bleeding and prognostic implications of different strategies - a multicentre registry	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0161	Dr Chibana Hidetoshi	Evaluation of coronary endothelial function and angioscopic findings after 1st generation and 2nd generation DES implantation for ACS	**Coronary Interventions**	NSTEMI/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS0164	Dr URA Yujiro	Efficacy of 3-dimentional optical frequency domain imaging on optimisation of coronary bifurcation stenting	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0174	Dr Aramaki Kazuhiko	Serial assessment of vascular responses between platinum-chromium everolimus-eluting metallic stent (EES) and cobalt-chromium EES: an OCT analysis at baseline, one- and two-year follow-up	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0177	Prof Sang-Hoon Seol	Major predictors of long-term clinical outcomes after PCI for coronary bifurcation lesions with 2-stent strategy	**Coronary Interventions**	Bifurcation/ Stents and scaffolds	Level 2 Zone D
Euro16A-POS0180	Dr NAGAMATSU Wataru	Retrograde approach has the advantage for very difficult cases of chronic coronary total occlusion: sub-analysis of Japanese multicenter registry	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0182	Dr NAGAMATSU Wataru	Predictors of retrograde approach success for chronic coronary total occlusion: sub-analysis of Japanese multicenter registry	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0183	Dr. Emanuela Piccaluga	Occupational radiation-induced cataract in catheterisation personnel: results of an Italian survey	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0201	Mr Ueshima Daisuke	The obesity paradox after second-generation DES implantation	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0203	Mrs Xu Jingjing	The effect of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after PCI between Ticagrelor and Clopidogrel	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0215	Dr Wanha Wojciech	First and second-generation DES versus bare-metal stents in all comer population of patients undergoing PCI of SVG in 1-year follow-up	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0218	Dr Özel Erdem	Procedural and one-year clinical outcomes of BRS for the treatment of CTO: a single-centre experience	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0219	Dr BOUSSAID Houssem	Relationship between Galectin-3 levels in STEMI and the burden of atherosclerosis	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0220	Dr DÖRR Oliver	Propensity score matching analysis of currently available BRS in the clinical setting of ACS	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0231	Dr Suzuka Yuki	Efficacy of 7fr glidesheath in transradial coronary intervention in comparison with 7.5fr sheathless guiding catheter	**Coronary Interventions**	Other coronary	Level 2 Zone E

Euro16A-POS0235	Mr Fukushima Taku	OCT-guided treatment for in-stent restenosis using DEB angioplasty	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0238	Dr Surowiec Slawomir	Does the effectiveness of recanalisation of chronic occlusion depend on the location of obstruction?	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0239	Prof Woo Jong Shin	Aortic arch calcification on chest X-ray combined with coronary calcium score show additional benefit for diagnosis and outcome in patients with angina	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0242	Dr Asami Masahiko	Impact of stent type and prolonged DAPT on long-term clinical outcomes in haemodialysis patients with coronary artery disease	**Coronary Interventions**	Stable CAD/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS0253	Dr Isawa Tsuyoshi	Safety and efficacy of transradial PCI using sheathless guiding catheters for ACS: a prospective study with radial ultrasound follow-up	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0256	Dr Isawa Tsuyoshi	Transradial PCI for ACS using sheathless guiding catheters do not cause a delay in reperfusion	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0268	Dr Ho Hee Hwa	Clinical efficacy and safety of drug-coated balloon angioplasty as primary therapy / adjunctive therapy in primary PCI (nine-month clinical follow-up)	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0281	Dr Córdoba Soriano Juan Gabriel	Periprocedural management and bleeding complications of patients under chronic oral anticoagulation undergoing primary angioplasty	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0284	Dr Córdoba Soriano Juan Gabriel	Technical complexity of the use of Absorb in comparison with Xience: is there an important difference?	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0286	Dr TALAMALI Amrane	Impact of delays of reperfusion of STEMI on angiographic results of thrombolysis	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0289	Dr TALAMALI Amrane	Is the admission hyperglycemia during STEMI a predictive factor for undiagnosed diabetes?	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0291	Dr TALAMALI Amrane	Hyperglycemia on admission and coronary reperfusion therapy during the acute phase of a STEMI in non-diabetic patients	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0293	Dr TALAMALI Amrane	The stress hyperglycemia in the acute phase of a STEMI: a residual risk in the era of primary angioplasty?	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0295	Mr OTTERSPOOR Luuk	Intracoronary hypothermia for acute myocardial infarction in the isolated beating pig heart	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0300	Dr Kinnaird Tim	PCI with DES versus CABG for isolated proximal left anterior descending coronary disease: a systematic review and meta-analysis	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0305	Dr Kinnaird Tim	Early clinical experience with a polymer-free biolimus A9 drug-coated stent in DES-type patients who are poor candidates for prolonged DAPT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0312	Dr Kang Sangwook	The effect of admission blood glucose and hemoglobin A1C on prognosis of diabetic patients with acute myocardial infarction : from KorMI registry	**Coronary Interventions**	STEMI	Level 3 Zone I

Euro16A-POS0314	Dr Caixeta Adriano	Impact of intravascular imaging on short- and long-term clinical outcomes following implantation of the Absorb BVS: a propensity score-matched analysis	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0315	Dr Dai Yuxiang	The efficacy and safety of the transradial versus transfemoral approaches for intervention therapy in bypass grafts of patients underwent CABG	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0318	Dr OHTANI Hirofumi	Longitudinal distribution of neointimal hyperplasia and strut coverage following new generation DES using OCT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0323	Dr Andersson Jonas	Clinical experiences from Nanothin Polyzene-F coated coronary stents in a high-risk opulation	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0336	Dr Kulikovskikh Yaroslav	Long-term outcomes of BRS for STEMI treatment	**Coronary Interventions**	STEMI/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS0337	Dr Yano Hideki	Comparison of pre-dilation with scoring balloons vs. conventional balloons (or direct stenting) for coronary stenting analysed with OCT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0339	Prof SCHROEDER Erwin	Quality control of interventional cardiology : objective assessment by the NCDR CathPCI risk score system : a single-centre experience (1997-2014)	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0342	Mrs moreira Adriana	Desire risk score for prediction of in-hospital and late follow-up major adverse cardiac events (MACE) after PCI with DES	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0349	Prof Jang Jae-Sik	Impact of combined use of neutrophil to lymphocyte ratio and c-reactive protein on clinical outcomes in patients with acute myocardial infarction	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0363	Ms TSUCHIYA Hiroko	Calcification, rather than lipid-laden neointima, is a predominant components of neoatherosclerosis in hemodialysis patients : from a consecutive frequency domain OCT study	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0366	Prof Siminiak Tomasz	Male patients undergo more difficult and more expensive percutaneous coronary procedures despite younger age	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0367	Prof Siminiak Tomasz	Age correlates with procedural and fluoroscopy times in patients undergoing angioplasty from radial approach but not from femoral approach	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0381	Dr Cook Christopher	Can computational fluid dynamics (CFD) predictions of FFR agree with invasive FFR in intermediate stenoses?: lessons from a study using OCT and invasive measures of coronary flow	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0387	Dr GORYO Yutaka	Neointimal condition after second generation DES implantation is not affected by continuing DAPT beyond nine months	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0390	Mrs Bento Dina	Crusade bleeding score: is it still a good score to prevent bleeding?	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0394	Dr Chung Jaehoon	Vasodilating beta blockers are superior to conventional beta blockers in preventing major cardiovascular events in patients with myocardial infarct (from Korea acute myocardial infarction registry)	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0405	Mr BOEDER Niklas	Implantation of BRS in patients with indication for oral anticoagulation: is it safe?	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H

Euro16A-POS0407	Dr Camacho Freire Santiago Jesus	PCI in patients at high-risk of bleeding with polymer-free and carrier-free drug-coated stent (Biofreedom): multicentre all-comers registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0408	Mr BOEDER Niklas	Influence of plaque composition and morphology on DESolve novolimus-eluting BRS implantation	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0417	Prof Siminiak Tomasz	Analysis of x-ray dosing of angioplasty procedures in real life patients with ACS	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0419	Dr Markovic Sinisa	24-month clinical results after recanalisation of true CTO with the sirolimus-eluting Orsiro stent	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0420	Prof Siminiak Tomasz	Determinants of cathlab costs in patients undergoing coronary angioplasty during ACS	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0422	Dr Markovic Sinisa	Long-term clinical results of bioresorbable drug-eluting scaffolds in patients with and without diabetes	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0429	Mrs Roa-Garrido Jessica	BRS in ACS setting: events and DAPT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0431	Dr Ding Wern Yew	Diagnostic accuracy and outcome of an iFR-incorporated approach to revascularisation	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0432	Dr Calmac Lucian	From rest to hyperemia: initial validation of a data-driven approach for functional assessment of coronary lesions	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0436	Dr Verdoia Monica	Radial vs. femoral approach in ACS: a comprehensive meta-analysis of randomised trials	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0442	Mrs Bento Dina	Predictors of one-year mortality in patients with previous PCI admitted for ACS	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0446	Dr Meneguz-Moreno Rafael Alexandre	Comparison of estimated chronic kidney disease epidemiology collaboration equation and cockroft-gault to predict contrast-induced nephropathy after PCI	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0453	Mrs Morales María José	Bivalirudin as the first line anticoagulant therapy in elderly patients undergoing PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0468	Dr Camacho Freire Santiago Jesus	Short versus long DAPT in patients at high-risk of bleeding treated with polymer-coated stent without Biolimus (Biofreedom): multicentre all-comers registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0469	Mr Park Keun-Ho	Evaluation of efficacy and safety of biolimus A9TM-eluting stent in patients with ACS: a multicentre observational study (BEAUTY study)	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0474	Dr Adrega Tiago	Early clinical experience in the utilisation of DEB: safety, efficacy and challenging clinical scenarios of a single catheterisation laboratory	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0475	Dr Adrega Tiago	Expanding the utilisation of BRS in increasingly challenging clinical scenarios: the summed experience of a cardiac catheterisation laboratory	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H

Euro16A-POS0477	Dr Cho Sang Cheol	The benefits of bisoprolol were comparable with carvedilol in secondary prevention of acute myocardial infarction patients who underwent PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0478	Dr Cho Sang Cheol	Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level of triglyceride and high-density lipoprotein cholesterol	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0479	Dr Cho Sang Cheol	Is routine combination of renin-angiotensin system blocker and beta blocker beneficial in low-risk myocardial infarction patients?	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0481	Dr Cho Sang Cheol	Different clinical implication of high-degree atrioventricular block complicating STEMI according to the location of infarct in the era of primary PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0485	Prof CHOI Tae-Young	Prediction of major adverse cardiovascular events using annual coronary artery calcium score progression rate combined with baseline coronary artery calcium score in asymptomatic Korean population	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0489	Prof French John	Influence of age and gender on clinical outcomes following PCI for ACS	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0490	Prof French John	Clinical outcomes of patients with chronic kidney disease and STEMI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0491	Mrs Kochergina Anastasia	Predictors of coronary angiography non-perfomance in STEMI patients	Coronary Interventions	STEMI	Level 3 Zone I
Euro16A-POS0492	Dr Park Sang Don	Comparison of outcomes after aspiration thrombectomy with versus without preceding balloon angioplasty in STEMI: data from INTERSTELLAR registry	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0493	Dr Zhang Dong	Incidence, causes and clinical outcomes of PCI related periprocedural myocardial infarction (diagnosed by using the definition proposed by Society for Cardiovascular Angiography and Interventions in 2013)	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0497	Dr HAMONANGAN Rachmat	impact of frailty on 30-days major cardiac events in elderly patients with coronary artery disease underwent elective PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0498	Dr Perez Guzman Joaquin	Validation of bleeding risk scores in elderly patients undergoing PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0501	Dr Zhang Dong	Can "true bifurcation lesions" really be considered an independent risk factor of acute side branch occlusion after main vessel stenting? A retrospective analysis of 1200 consecutive bifurcation lesions in a single-centre	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0506	Dr HAMONANGAN Rachmat	CTO in angioplasty: high cost intervention vs. limited resources	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0527	Dr Naguib Badie Tamer	Bleeding and major adverse cardiac events in non-cardiac surgery, within two years post PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0554	Dr IBN ELHADJ Zied	Percutaneous interventions in adult patients with ectopic origin of the coronary arteries: a single-centre experience	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0563	Dr Venetsanos Dimitrios	Inhibition of platelet aggregation after administration of three different ticagrelor loading dose formulations	**Coronary Interventions**	Stable CAD	Level 2 Zone E

Euro16A-POS0567	Dr SOTOMI Yohei	Gender difference of five-year clinical outcomes following coronary artery bypass surgery vs. DES implantation: analysis of pooled data from SYNTAX, BEST, and PRECOMBAT randomised controlled trials	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0569	Dr WIEBE Jens	Angiographic and clinical outcomes of patients treated with everolimus-eluting BRS in a real-world setting: two-year results of the ISAR-ABSORB registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0574	Dr Wassef Nancy	Value of the RenalGuard system in coronary interventions	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0577	Dr Moustafa Tamer	Value of S'-wave dispersion of mitral annular tissue velocity in predicting the presence of significant coronary artery stenosis	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0579	Dr Moustafa Tamer	The relation between coronary artery disease severity and fragmented QRS complex in patients with left bundle branch block	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0582	Dr BICHO AUGUSTO Joao	Is double antiplatelet therapy with triflusal an alternative to aspirin after PCI?	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0583	Dr Kumar Nitin	Single-centre experience of Stentys Xposition in treatment of left main stem lesions	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0585	Prof Mosseri Morris	The effect of cumulative exposures to contrast media on contrast-induced nephropaty	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0588	Dr Cho Jae Young	OCT-guided PCI: clinical impact of acute abnormal findings after DES implantation detected only by OCT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0589	Dr Cho Jae Young	Effects of bioabsorbable vs. durable polymer DES on neoatherosclerosis: OCT analysis	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0590	Dr Kagawa Eisuke	Angiographic success and short-term outcomes in coronary revascularization for comatose survivors of cardiac arrest treated with targeted temperature management	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0592	Dr BEN ALI Imen	Adverse events after premature discontinuation of clopidogrel in post-ACS patients: insights from a Tunisian centre	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0593	Dr Yao Yi	Correlation between expression level of platelet endothelial aggregation receptor 1 and on-aspirin platelet aggregation after PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0597	Dr Marti David	Impact of baseline hematocrit on bleeding events after PCI in the elderly	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0601	Dr Jurado-Roman Alfonso	PCI of coronary bifurcation lesions in current real practice	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0605	Mr Rozemeijer Rik	The clinical performance of a novel bioengineered DES with a short duration of DAPT in patients at risk for major bleeding, the first results of the Combo-TAVI registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0607	Dr Maximkin Daniil	Five-year results of endovascular treatment of parients with ischaemic heart disease using second and third generation DES	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H

Euro16A-POS0613	Dr Freitas Pedro	CABG vs. PCI in NSTEMI patients with multivessel disease: a propensity score analysis	**Coronary Interventions**	NSTEMI/ Left main and MVD	Level 3 Zone I
Euro16A-POS0618	Dr Silveira Inês	PCI in unprotected left main disease: in-hospital and mid-term outcomes	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0620	Dr BOUKERCHE Farouk	Predictors of reintervention in patients with CABG	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0631	Dr Takeshi Ijichi	Comparisons of vascular reaction between biodegradable polymer based sirolimus and permanent polymer based everolimus eluting stents in porcine coronary artery	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0633	Dr Karamfiloff Kiril	Occlusion of secondary side branches after stenting coronary bifurcation lesions predicts recurrence of symptoms of angina or congestive heart failure at mid-term follow-up (up to 60 months) from intracoronary electrocardiogram (ECG) and myonecrosis after bifurcation stenting (COSIBRIA&CO) (ClinicalTrials.gov Identifier:NCT01268228)	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0637	Dr LEE Jun-Won	Transradial intervention is a strong predictor for reducing all-cause death in patients with STEMI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0638	Dr LEE Jun-Won	Transradial intervention is a strong predictor for all-cause death and does not delay procedure time in routine practice (five-year single-centre experience)	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0645	Dr Amat-Santos Ignacio J	Distal vessel quality score as predictor of outcomes after aortocoronary bypass graft	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0649	Dr Campos Carlos M.	Accuracy of high-sensitivity troponin and high-sensitivity C-reactive protein in detecting plaque complexity by OCT	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0650	Dr Maximkin Daniil	Bioabsorbable scaffolds for patients with diabetes mellitus	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0655	Dr Moriyama Noriaki	10-year clinical outcomes in patients with unprotected left main coronary artery disease after PCI with bare metal stent	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0659	Dr JOMAA Walid	Temporal trends in STEMI management and prognosis over 17 years in a Tunisian centre	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0661	Dr SAAD Mohammed	BRS in a real-world patient population: results from a mid-term angiographic follow-up	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0662	Dr SANCHEZ-ESPINO Alejandro	Efficacy and safety of transradial percutaneous revascularisation for unprotected left main stenosis: comparison with transfemoral approach	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0663	Dr Herrera Nogueira Raúl	Primary PCI of bifurcation culprit lesions in STEMI: predictors of angiographic success	**Coronary Interventions**	STEMI/ Bifurcation	Level 3 Zone I
Euro16A-POS0673	Dr Koganti Sudheer	Enhanced microparticle mediated thrombin generation in stable and unstable coronary artery disease	**Coronary Interventions**	NSTEMI/ stable CAD	Level 3 Zone I
Euro16A-POS0679	Dr Derimay Francois	Provisional bifurcation stenting by Re-POT with last generation of DES	**Coronary Interventions**	Bifurcation	Level 2 Zone D

Euro16A-POS0682	Dr Leite Luís	High-sensitivity cardiac troponin improves risk stratification of stable angina patients	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0700	Dr GHOSE Tapan	Effect of antiproliferative drug concentration on short term outcomes in patients undergoing second generation DES implantation	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0702	Dr GHOSE Tapan	Real-world experience of BRS deployment with follow-up results from Paras Hospital: Paras BRS study	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0703	Dr Dharma Surya	Universal time metrics in STEMI care revisited: interhospital transfer creates longer reperfusion time and focusing the door-in to door-out time rather than door-to-device time may improve the total ischaemia time in STEMI patients transferred for primary PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0704	Prof KIM Sang-Hyun	Evaluation of optimising clinical factors for DEB angioplasty for in-stent restenosis	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0706	Dr Dharma Surya	No sex disparities of reperfusion therapy for STEMI patients admitted to a tertiary care academic hospital	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0713	Prof Carrié Didier	Evaluation of the antirestenotic effect of a drug eluting balloon after bare metal stent implantation in de novo lesions using angiography and OCT imaging: the Biolux II trial.	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0715	Dr Otsuki Shuji	Relationship between filter no-reflow phenomenon and pathological characteristics of captured debris with filter distal protection devices in ACS	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0725	Mr HOLLANDER Maurits	Non-invasive assessment of collateral circulation in the hand prior to transradial catheterisation: validation and relation to clinical outcome after one month	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0728	Prof CHOI Seongil	The six-month fate of patients with very low value of P2Y12 reaction units (PRU)	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0730	Ms Kalkman Deborah	Shortened DAPT in patients treated with the bio-engineered sirolimus-eluting stent in the REMEDEE registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0735	Dr MEJÍA-RENTERÍA Hernán David	Impact of Medina classification 1,1,1 bifurcation culprit lesion on PCI success and clinical outcomes in patients with STEMI	**Coronary Interventions**	STEMI/ Bifurcation	Level 3 Zone I
Euro16A-POS0736	Dr BOUKERCHE Farouk	Predictors and prognosis of early ischaemic mitral regurgitation during ACS treated by PCI	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0740	Dr FRANCISCO Ana Rita	Angioplasty in CTO: results of a 12-month registry	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0744	Dr GOMEZ MENCHERO Antonio Enrique	Treatment of "real small coronary arteries" with a paclitaxel-coated balloon catheter (SeQuent Please) and bare metal stent (Coroflex Blue): small Please multicentre registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0764	Dr Adjedj Julien	Reversed single string technique for coronary bifurcation stenting: first report in vitro case demonstrations	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS0767	Dr Adjedj Julien	Saline-induced maximal coronary hyperemia: usefulness for quantitative assessment of microvascular function by coronary thermodilution	**Coronary Interventions**	Other coronary	Level 2 Zone E

Euro16A-POS0780	Dr Tzafriri Abraham	Solubility controlled sirolimus release from drug-filled stents	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0781	Mr Moura Guedes João Pedro	Predictors of normal coronary arteries in patients admitted with ACS	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0782	Mr Moura Guedes João Pedro	ACS and left main coronary disease: predictors of in-hospital mortality and one-year follow-up mortality	**Coronary Interventions**	Left main and MVD	Level 2 Zone D
Euro16A-POS0787	Dr Foin Nicolas	Overexpansion capacity and stent design model selection: an update with contemporary DES platforms	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0789	Dr Yamaji Kyohei	Very late scaffold thrombosis: a systematic review	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0790	Prof Dong-Bin Kim	Four-year clinical outcomes of overlapping everolimus-eluting stents	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0791	Prof Dong-Bin Kim	Comparison of long-term and short-term mortality STEMI treated with primary PCI vs. unstable angina / NSTEMI and stable angina treated with PCI in DES era	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0798	Mr Fernandez Luis	STEMI results in a university hospital: comparison between conventional primary PCI and thrombus aspiration	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0799	Prof Cho Yun-Kyeong	Gender difference of plaque characteristics in intermediate lesion assessed by OCT	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0800	Prof Cho Yun-Kyeong	Comparison of everolimus- and zotarolimus-eluting stents in patients with renal insufficiency	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0802	Dr Lee Min-Ho	Long-term natural course and clinical outcomes of coronary spasm : result from follow-up ergonovine provocation test	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0803	Dr Lu Hao	Prognosis value of left ventricular dyssynchrony pre-revascularisation by gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) phase analysis in conorany CTO patients post-revascularisation	**Coronary Interventions**	CTO	Level 2 Zone D
Euro16A-POS0809	Mr Fernandez Luis	Intraortic balloon pump haemostasis with the Angio Seal device	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0830	Mrs Veldhof Susan	Challenges in achieving guidelines recommended cholesterol levels and risk factors associated with not achieving the target: insights from the Absorb-II randomised clinical trial	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0849	Dr Hahn Joo-Yong	Glycemic control after PCI and long-term clinical outcomes in patients with type 2 diabetes mellitus	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0850	Dr Mori Takahiro	Impact of bifurcation culprit lesions on clinical outcome and plaque orientation in acute myocardial infarction	**Coronary Interventions**	STEMI/ Bifurcation	Level 3 Zone I
Euro16A-POS0851	Dr Hahn Joo-Yong	Modified residual SYNTAX score and clinical outcomes in patients with multivessel disease undergoing PCI	**Coronary Interventions**	Left main and MVD	Level 2 Zone D

Euro16A-POS0858	Dr Yildiz Bekir	Stop and think again during PCI: effect of coronary thrombus aspiration in all ACS - patients on three-year survival	**Coronary Interventions**	STEMI/ NSTEMI	Level 3 Zone I
Euro16A-POS0869	Dr Atique Syed	The CRUSADE score is useful in stratifying risk of major bleeding and death following STEMI PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0871	Dr Camacho Freire Santiago Jesus	ACS in normal or near-normal coronary angiography (NONCA): diagnosis, management and outcomes in a long-term follow-up	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0874	Mrs liu Rong	Correlation of the prognosis of alcohol septal ablation in hypertrophic obstructive cardiomyopathy and the characteristics of septal branch	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0879	Dr Amin Reshma	Triple therapy with DAPT and novel oral anticoagulant (NOAC) is safe and effective following PCI : a "real-world" analysis	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0881	Dr Camacho Freire Santiago Jesus	ACS in normal or near-normal coronary angiography (NONCA): a coronary imaging techniques ccomparison	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0882	Dr Mansour Samer	Real-world clinical Impact of paclitaxel-eluting balloon angioplasty compared to second-generation DES for treatment of in-stent restenosis in a primarily ACS all-comers population	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0883	Dr Spartera Marco	Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a single-centre experience	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0884	Ms CHODVADIYA Poonam	Long-term safety and efficacy of a novel abluminal coated sirolimus-eluting stent in a diabetic patient population: two-year report of the large, multicentre en-ABL e-registry	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0886	Dr Camacho Freire Santiago Jesus	Radial and ulnar patency evaluated by vascular-doppler after cardiac catheterisation in a medium to long term follow-up	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0887	Dr Sgueglia Gregory	Clinical and angiographic performance of polymer-free biolimus-eluting stent in patients with acute STEMI in a metropolitan public hospital	**Coronary Interventions**	STEMI/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS0890	Prof Hong Seung Pyo	Clinical outcomes following stent thrombosis of DES in Korean single-centre	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0892	Prof LEE Sang Yeub	Clinical impact of platelet reactivity and gene polymorphisms in patients with ischaemic heart disease after PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0898	Prof Hong Seung Pyo	Clinical usefulness of cardiac computerised tomography angiography as follow-up modality in PCI compared to coronary angiography	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0900	Dr Aurigemma Cristina	Clinical impact of routine angiographic follow-up after PCI on unprotected left main or chronic total occlusive lesions	**Coronary Interventions**	Left main and MVD/ CTO	Level 2 Zone D
Euro16A-POS0901	Dr Janas Adam	Comparabe vascular response of a new generation sirolimus-eluting stents when compared to everolimus-eluting stents in the porcine coronary restenosis model	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0915	Mrs BALCI Kevser	Predictors of impaired reperfusion after PCI in patients with in-hospital acute stent thrombosis: retrospective analyses of five-year data	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H

Euro16A-POS0917	Dr ZALEWSKI Jaroslaw	The immediate percutaneous intervention after bypass surgery complicated by periprocedural myocardial infarction may improve clinical outcomes	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0921	Mrs BALCI Kevser	Relationship between end-procedural activated clotting time values and radial artery occlusion rate with standard fixed dose heparin after transradial cardiac catheterisation	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0922	Dr TOTH G Gabor	Reduced coronary flow reserve in coronary arteries without stenosis: impact of various haemodynamic and clinical parameters	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0929	Ms de Waard Guus	Comparison between thermodilution and doppler flow velocity derived quantification of microvascular function after STEMI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0943	Prof Hong Seung Pyo	Recent trends of access site for coronary intervention in Korea	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0953	Mr Leon Jimenez Javier	Iatrogenic coronary dissection: characteristics, management and long-term follow-up	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0954	Dr Xanthopoulou Ioanna	Contemporary antiplatelet treatment in ACS patients undergoing PCI: one-year outcomes from the GReekAntiPlatelet Registry (GRAPE)	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0957	Dr Gaskina Anna	Incidence, risk factors and prognostic value of contrast induced acute kidney injury in patients with stable angina pectoris and elective percutaneous intervention	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0958	Dr AL NOORYANI Arif	Initial results of robotic-assisted PCI for the treatment of patients with stable angina and ACS	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0962	Dr Kőszegi Zsolt	Smart calculation of the virtual functional assessment index with separate determination of the laminar and turbulent flow resistance	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0965	Dr Gaskina Anna	Short-term Rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with NSTE-ACS and delayed percutaneous intervention	**Coronary Interventions**	NSTEMI	Level 3 Zone I
Euro16A-POS0966	Dr Clermont Gaelle	Endovascular creation of a rabbit saccular aneurysm model	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS0968	Dr Blachut Aleksandra	Femoral access with vascular closure device vs. radial access for PCI with early same-day discharge	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0969	Prof Hong Seung Pyo	Transradial-prone patients and lesions in real-world practice of Korea	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0970	Dr Xanthopoulou Ioanna	One-year non-persistence with discharge P2Y12 receptor anatagonists in ACS patients undergoing PCI: insights into GReekAntiPlateletrEgistry (GRAPE) Study	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0971	Dr Gaskina Anna	Risk factors and outcomes of contrast-induced acute kidney injury in patients undergoing PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS0975	Dr Blachut Aleksandra	Safety of very early discharge after PCI including multivessel disease and bifurcation lesions in stand-alone centre	**Coronary Interventions**	Left main and MVD/ Bifurcation	Level 2 Zone D

Euro16A-POS0977	Dr AL NOORYANI Arif	Initial experience with first 300 Absorb BRS PCI in all-comers population in large volume single-centre study	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0978	Dr Kiatchoosakun Songsak	Impact of left ventricular function on hospital mortality in patients undergoing PCI: results from Thai Percutaneous Coronary Intervention Registry (TPCIR)	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0981	Prof Gori Tommaso	The ratio of final minimum lumen diameter to nominal diameter predicts bioresorbable coronary scaffold thrombosis: an easy marker to predict an ominous complication	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0987	Dr Lagos Oscar	Evolution and prognosis: analysis of patients with out-of-hospital cardiopulmonary arrest those who performed coronary angiography	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS0992	Mr JIMENEZ Gustavo	Mild hypothermia in ACS: should we use glycoprotein IIb/IIIa inhibitors in these patients?	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0994	Dr AL NOORYANI Arif	First clinical experience with DESolve Scaffold System PCI in all-comers population in UAE single centre study	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS0995	Dr Sato Tomohiko	Difference between outcomes of non-left main trunc bifurcation lesions treated with two-stent strategy, analysed according to stenting techniques, and lesion locations	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS1003	Dr Sgueglia Gregory	Can simultaneous kissing stent (SKS) be performed when using a six French guiding catheter? A multidevice mutioperator bench test	**Coronary Interventions**	Bifurcation	Level 2 Zone D
Euro16A-POS1008	Dr Sgueglia Gregory	The first international drug-coated balloon survey: Europe vs. rest of the world	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS1011	Dr Hennigan Barry	Validation of the "smart" minimum algorithm for determining FFR	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1013	Dr Kovarnik Tomas	Cystatin C is associated with the extent and characteristics of coronary atherosclerosis in patients with preserved renal function	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1028	Dr Reis Liliana	GRACE score and ischaemic risk prediction in ACS: does it fit all ages?	**Coronary Interventions**	NSTEMI	Level 3 Zone I
Euro16A-POS1035	Mrs Zwaan Eva	Upper extremity function after transradial PCI: preliminary results	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1038	Dr Hong Sung-Jin	The effect of sex and anthropometry on outcomes after PCI for complex coronary lesions: an IVUS study	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS1046	Dr Danson Edward	Percutaneous revascularisation versus medical therapy in a surgically ineligible cohort	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1047	Dr KOIFMAN Edward	Radial vs. femoral access in complex coronary lesions interventions: one-year outcomes of a single-centre experience	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1049	Dr Konstantinou Klio	Patient and operator factors influencing the conversion from transradial to transfemoral access in coronary procedures	**Coronary Interventions**	Other coronary	Level 2 Zone E

Euro16A-POS1050	Dr Katsikis Athanasios	Long-term effects of SPECT-findings based PCI on hard cardiac endpoints in octogenarians	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1058	Ms López-Lluva María Thiscal	Thrombus aspiration during PCI, which patients may benefit from it?	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS1060	Prof Omerovic Elmir	First generation DES is not better than contemporary bare metal stent after long-term follow-up: a report from SCAAR	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS1069	Ms Fox Maule Camilla	Bioresorbable stent fracture: discordance in detection between 2D and 3D OCT	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS1076	Dr Hernandez Felipe	Bioresorbable coronary devices in STEMI patients: immediate and 30-day results of the REPARA registry	**Coronary Interventions**	STEMI/ Stents and scaffolds	Level 3 Zone I
Euro16A-POS1082	Dr Malik Nadim	Post-PCI mynx femoral closure device in real-world cohort: single-centre experience	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1084	Dr MAKOWSKI Marcin	Impact of catheter lenght on radiological exposure for patient and operator using radial or femoral approach	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1089	Dr Dursun Huseyin	GuideLiner catheter application in complex coronary lesions: largest experience of our country	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1095	Dr Costa Ricardo	Impact of baseline lesion complexity on long-term clinical outcomes following PCI with DES	**Coronary Interventions**	Stents and scaffolds	Level 3 Zone H
Euro16A-POS1098	Dr Moon Donggyu	Impact of high-intensity statin therapy on clinical outcomes in patients undergoing PCI	**Coronary Interventions**	Stable CAD	Level 2 Zone E
Euro16A-POS1099	Dr Moon Donggyu	Variability in hemoglobin A1c predicts clinical outcomes in patients with asymptomatic type 2 diabetes	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1100	Dr Moon Donggyu	Long-term clinical outcomes of newly diagnosed diabetes and prediabetes among patients with acute myocardial infarction	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS1101	Prof Sedding Daniel	Local inhibition of microRNA-146a prevents neointima formation	**Coronary Interventions**	Other coronary	Level 2 Zone E
Euro16A-POS1102	Dr Doost Hosseiny Ataollah	Symptom to balloon time is a strong predictor of major adverse cardiac events (MACE) following primary PCI: results from the Australian Capital Territory STEMI Registry	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS1103	Dr Doost Hosseiny Ataollah	Mortality pattern and cause of death in a long-term follow-up of STEMI patients treated with primary PCI	**Coronary Interventions**	STEMI	Level 3 Zone I
Euro16A-POS0129	Dr Moncalvo Cinzia	Renal denervation: more ablative points major reduction in blood pressure?	**Interventions for Hypertension and Stroke**	Renal denervation	Level 2 Zone B
Euro16A-POS0148	Dr tanboga Ibrahim	Carotid artery stenting vs. endarterectomy: do we need more evidence? - A meta-analysis plus trial sequential and clinical vs. statistical significance analyses	**Interventions for Hypertension and Stroke**	Carotid stenting	Level 2 Zone B

Euro16A-POS0163	Dr Moncalvo Cinzia	Carotid artery stenting: is it possible to reduce complications?	**Interventions for Hypertension and Stroke**	Carotid stenting	Level 2 Zone B
Euro16A-POS0302	Prof Reuter Hannes	Controlling and lowering blood pressure with the MobiusHD device: first-in-man interim results (CALM-FIM study)	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B
Euro16A-POS0351	Dr Ferrante Giuseppe	Endovascular treatment vs. intravenous thrombolysis alone for ischaemic stroke: meta-analysis of randomised controlled trials	**Interventions for Hypertension and Stroke**	Ischemic stroke	Level 2 Zone B
Euro16A-POS0541	Dr VELÁZQUEZ Maite	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: Spanish experience	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B
Euro16A-POS0555	Dr STOLYAROV Dmitry	Staged surgical and endovascular revascularisation in patients with carotid and coronary lesions	**Interventions for Hypertension and Stroke**	Carotid stenting	Level 2 Zone B
Euro16A-POS0602	Dr Kleinecke Caroline	LAA occlusion with second generation device: a real-world experience	**Interventions for Hypertension and Stroke**	LAA closure	Level 2 Zone B
Euro16A-POS0615	Dr Van Langenhove Glenn	Non-invasive isolation of pulmonary veins in the treatment of atrial fibrillation	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS0640	Prof BERGMANN Martin	Initial experience with the new Watchman FLX LAA Occluder The ALSTER LAA FLX registry: procedural data and implantation details	**Interventions for Hypertension and Stroke**	LAA closure	Level 2 Zone B
Euro16A-POS0685	Prof KOH Kwang	Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B
Euro16A-POS0686	Prof KOH Kwang	Vascular and metabolic effects of ezetimibe depend on dosages of simvastatin in patients with hypercholesterolemia	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B
Euro16A-POS0711	Dr Dinis Paulo	Left atrium percutaneous closure in high-risk patients	**Interventions for Hypertension and Stroke**	LAA closure	Level 2 Zone B
Euro16A-POS0716	Dr Paunovic Dragica	Renal sympathetic denervation in uncontrolled hypertension patients: a feasibility study	**Interventions for Hypertension and Stroke**	Renal denervation	Level 2 Zone B
Euro16A-POS0749	Dr FRANCISCO Ana Rita	Renal sympathetic denervation: impact on hypertensive disease	**Interventions for Hypertension and Stroke**	Renal denervation	Level 2 Zone B
Euro16A-POS0751	Dr FRANCISCO Ana Rita	Effect of renal sympathetic denervation in systemic sympathetic modulation and glucose metabolism	**Interventions for Hypertension and Stroke**	Renal denervation	Level 2 Zone B
Euro16A-POS0786	Dr Hudzik Bartosz	Von Willebrand factor in patients on mechanical circulatory support	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0806	Dr Lurina Baiba	Latvian LAA closure registry: five years of experience in high-risk patients	**Interventions for Hypertension and Stroke**	LAA closure	Level 2 Zone B
Euro16A-POS0831	Dr Khafizov Radik	Fractionated flow reserve of haemodynamically significant renal artery stenosis measurement and IVUS in patients with renovascular hypertension	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B

Euro16A-POS1067	Dr Janas Adam	Early and long term outcomes after carotid stenting in symptomatic vs. asymptomatic patients	**Interventions for Hypertension and Stroke**	Carotid stenting	Level 2 Zone B
Euro16A-POS0040	Dr ABAWI Masieh	Rationale and design of the Edwards SAPIEN-3 periprosthetic leakage evaluation vs. Medtronic CoreValve in transfemoral aortic valve implantation (ELECT) trial: a randomised comparison of balloon-expandable vs. self-expanding transcatheter aortic valve prostheses	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0046	Dr D´Ancona Giuseppe	TAVI with the direct flow medical prosthesis: single-centre short-term clinical and echocardiographic outcomes	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0052	Dr Dimitriadis Zisis	Impact of closure devices in TAVI procedures on vascular complications and mortality	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0053	Dr ABAWI Masieh	Effect of body mass index on clinical outcomes and all-cause mortality in elderly patients undergoing transcatheter aortic valve replacement	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0058	Dr ASHER Elad	The "burden" of TAVI patients admitted to the intensive coronary care unit. For the platelets and thrombosis in Sheba group (PLATIS-TAVI)	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0067	Dr Ruparelia Neil	Percutaneous transcatheter treatment for tricuspid bioprosthesis failure	**Interventions for Valvular Disease and Heart Failure**	Tricuspid/ Pulmonary valve	Level 3 Zone G
Euro16A-POS0068	Dr Ruparelia Neil	Long-term outcomes following TAVI from a single high volume centre (The Milan experience)	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0087	Dr RAHMAN Dr Md Toufiqur	Percutaneous transvenous mitral commissurotomy in patients with calcific mitral stenosis: immediate and in-hospital clinical, echocardiographic and haemodynamic outcome	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0089	Ms Cano-García Macarena	Comparison of logistic EuroSCORE, EuroSCORE II and STS score in predicting 30-day and one-year mortality in patients undergoing TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0092	Dr Perez de Prado Armando	No change in blood pressure or heart rate is evident after electrical stimulation of renal arteries in a swine model of hypertension	**Interventions for Hypertension and Stroke**	Other hypertension	Level 2 Zone B
Euro16A-POS0093	Dr Giordana Francesca	The Remote Ischemic Pre-conditioning Study to reduce Inflammation in patients undergoing TAVI: the RIPSI-TAVI Trial, a multicentre randomised pilot study	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0106	Dr Hammerstingl Christoph	Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0108	Dr D´Ancona Giuseppe	Percutaneous treatment of mitral valve regurgitation: the impact of previous neoplasia on long-term survival	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0116	Ms Xiong Tianyuan	Use of preparatory balloon aortic valvuloplasty during TAVI for better valve sizing	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0119	Prof RIBICHINI Flavio	Clinical outcomes of TAVI: from learning curve to proficiency	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0120	Prof RIBICHINI Flavio	Enhancing TAVI options further: emergency TAVI in left ventricle volume overload causing cardiogenic shock	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F

Euro16A-POS0135	Dr Zhu Da	Treatment of pure aortic regurgitation using a novel second-generation TAVI system (J-ValveTM System): initial clinical experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0136	Dr Zhu Da	Valve sizing for pure aortic regurgitation underwent TAVI: deep insight into deformation dynamic of aortic annulus in pure aortic regurgitation	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0139	Mr Bajoras Vilhelmas	A successful application of a 'hybrid' approach for transcatheter paravalvular leak closure of mitral prosthesis using specifically designed percutaneous devices in two patients	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0158	Dr JABBOUR Richard	TAVI has favourable outcomes in intermediate and low-risk populations	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0162	Dr Panoulas Vasileios	Survival of female patients with severe aortic stenosis after TAVI vs. surgical aortic valve replacement: a meta-analysis of randomised controlled trials	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0168	Dr Liao Yan-Biao	Comparison of 30-day results of TAVI in patients with stenotic bicuspid versus tricuspid aortic valves	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0196	Mr Onoda Hiroshi	Clinical benefit of low tube voltage CT angiography before TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0202	Ms Gerteis Esther	Short-term results and one-year data of a new self-expanding transcatheter aortic valve	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0208	Dr Schueler Robert	Impact of interventional edge-to-edge repair with the MitraClip system on mitral valve geometry: long-term results from a prospective single-centre study	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0210	Dr Schueler Robert	Two-year durability and outcome of interventional edge-to-edge repair with the MitraClip system in patients with primary and secondary mitral regurgitation	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0225	Dr Ruparelia Neil	The impact of procedural and clinical factors upon C reactive protein dynamics following TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0229	Dr Tichelbäcker Tobias	Percutaneous mitral valve repair and LAA closure in a single procedure: is that a reasonable approach?	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair/ LAA	Level 3 Zone F
Euro16A-POS0246	Mr Kortlandt Friso	Five years after percutaneous edge-to-edge mitral valve repair, what has happened?	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0252	Dr Sedaghat Alexander	Outcome in "event-free" TAVI: a potential means of identifying futile patients	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0262	Dr Fateh-Moghadam Suzanne	The incidence of pseudoaneurysm formation after TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0267	Prof Petronio Anna Sonia	Safety and efficacy of subclavian implantation of a fully repositionable and retrievable transcatheter heart valve	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G
Euro16A-POS0280	Dr Córdoba Soriano Juan Gabriel	Self-expandable transcatheter aortic valves programs in centres without on-site cardiac surgery: has the time of these centres come?	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G

Euro16A-POS0283	Dr Hiltrop Nick	Functional performance and quality of life in high-risk comorbid patients undergoing TAVI for symptomatic aortic valve stenosis	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0285	Dr Hiltrop Nick	Circumflex coronary artery injury after mitral valve surgery: a comprehensive review of the literature	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0303	Dr ALMEIDA-MORAIS Luis	Percutaneous PFO closure for secondary prevention after cryptogenic stroke: a 15-year experience study	**Interventions for Valvular Disease and Heart Failure**	ASD/ PFO closure	Level 3 Zone G
Euro16A-POS0327	Mr Jochheim David	Repositionable Lotus versus balloon-expandable Sapien 3 prosthesis regarding residual aortic regurgitation after transfemoral aortic valve implantation	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0341	Prof Hengstenberg Christian	Patients with peripheral artery disease undergoing TAVI for severe symptomatic aortic stenosis. Results from the BRAVO-3 trial	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0355	Dr NOMBELA-FRANCO Luis	Incidence, causes and impact of in-hospital infections following TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0362	Dr VAN WELY Marleen	Left subclavian artery as access site in TAVI using a new transcatheter aortic valve system	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0364	Dr De la Torre Hernandez Jose Maria	Dual vs. single antiplatelet therapy after transaortic valve implantation: a prospective multicentre study	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0377	Dr Cuchiara Michael	Transvenous neuromodulation of cardiac autonomic nerves improves haemodynamics	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0379	Ms Pokorny Saskia	Histological evaluation of mitral valved stents	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0403	Dr Stoller Michael	Impact of acute afterload reduction by TAVI on the human coronary circulation	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0413	Dr Romagnoni Claudia	Passive beating heart platform for testing transcatheter aortic, mitral and tricuspid valve therapies	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G
Euro16A-POS0414	Dr Taramasso Maurizio	Combined interventional valve procedures: initial experience with concomitant MitraClip and TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI/ Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0440	Dr Meneguz-Moreno Rafael Alexandre	Impact of paravalvular regurgitation on clinical outcomes after TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0450	Dr Frerker Christian	Transcatheter hybrid left ventricular reduction therapy for left ventricle aneurysm	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0455	Dr Gonska Birgid	Outcome after transfemoral aortic valve implantation with the balloon-expandable Edwards Sapien 3 valve for patients with severe symptomatic aortic stenosis: impact of valve size	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0456	Dr Deuschl Florian	Balloon- versus mechanical-expanding transcatheter heart valves: a comparison of procedural, haemodynamic, and clinical outcomes	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G

Euro16A-POS0461	Mr Matheus Simonato	Coronary obstruction following TAVI for degenerative bioprosthetic surgical valves: insights from the Valve-in-Valve International Data registry (VIVID)	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0464	Dr Deuschl Florian	Relevant aortic regurgitation after TAVI with second-generation devices: prevalence and causes	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0480	Mr Matheus Simonato	Impact of impaired renal function on survival following transcatheter aortic valve-in-valve implantation: insights from the Valve-in-Valve International Data registry (VIVID)	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0482	Dr KAZUNO Yoshio	Evaluation of the safety and feasibility of TAVI in patients with mega aortic annulus	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0487	Dr TENG Justin	A step by step technique to determine an overlap free projection for quality improvement and standardisation of contrast aortography	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0507	Mr NEYENS Jean Marie	The DISCOVER registry: one-year outcomes of a fully repositionable and retrievable non-metallic transcatheter aortic valve in a real-world population	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0511	Prof Maatouk Faouzi	Critical pulmonary valve stenosis of the newborn: early and long-term outcome	**Interventions for Valvular Disease and Heart Failure**	Tricuspid/ Pulmonary valve	Level 3 Zone G
Euro16A-POS0533	Prof Maatouk Faouzi	Balloon sizing at device closure of ASD: comparison between stop flow technique and the wasting in the balloon technique	**Interventions for Valvular Disease and Heart Failure**	ASD/ PFO closure	Level 3 Zone G
Euro16A-POS0546	Dr Schofer Niklas	A direct percutaneous transaxillary approach for implantation of a new self-expandable second generation transcatheter heart valve: first-in-human experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0558	Dr Tseng Elaine	Impact of size of transcatheter aortic valves on stent and leaflet stresses	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0571	Dr Madeira Marta	Percutaneous closure of patent foramen ovale: real-life registry for secondary prevention of paradoxical embolism	**Interventions for Valvular Disease and Heart Failure**	ASD/ PFO closure	Level 3 Zone G
Euro16A-POS0573	Dr SCHYMIK Gerhard	TAVIK-Registry: mortality and morbidity of low-risk patients. A comparison of TAVI with conventional surgery, results of a single-centre experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0586	Dr Wunderlich Nina	Impact of less invasive ventricular restoration on mitral regurgitation and ischaemic heart failure	**Interventions for Valvular Disease and Heart Failure**	Acute heart failure	Level 3 Zone F
Euro16A-POS0591	Dr Jansen Felix	Increased levels of circulating miRNA-21 and miRNA-423 are associated with left ventricular function improvement after transcatheter aortic valve replacement	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0608	Dr Solomonchuk Andrew	Acute heart failure in patients with ACS: a retrospective analysis	**Interventions for Valvular Disease and Heart Failure**	Acute heart failure	Level 3 Zone F
Euro16A-POS0610	Dr Freitas Pedro	Mean transvalvular gradient and indexed stroke volume have superior prognostic value than ejection fraction in patients submitted to TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0617	Dr Hayashida Kentaro	Incidence, predictors, and mid-term outcomes of leaflet thrombosis after TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F

Euro16A-POS0623	Mrs Fozilov Hurshid	Patients coronary heart diseases with low ejection fraction of left ventricle and state of their coronary arteries	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0628	Dr Pozzoli Alberto	Transapical approach for transcatheter mitral perivalvular leak closure: two-year outcomes of a single-centre experience	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0629	Dr Ichibori Yasuhiro	Comparison of different anti-thrombotic regimens after TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0639	Dr Abdul-Jawad Altisent Omar	Atrial fibrillation, transcatheter aortic valve replacement and antithrombotic therapy	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0653	Ms Zuk Katarzyna	Valve thrombosis after TAVI: frequency, timing and therapeutic management	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0656	Mr Kherad Behrouz	Postprocedural radial artery occlusion rate using a sheathless guiding catheter for left ventricular endomyocardial biopsy performed by transradial approach: establishing the Berlin RADial Access Score	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS0658	Mr Matheus Simonato	Implantation of novel balloon-expandable transcatheter heart valves into degenerated surgical aortic bioprostheses: matched comparison and insights from the Valve-in-Valve International Data registry (VIVID)	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G
Euro16A-POS0684	Dr Strong Christopher	Contemporary role of balloon aortic valvuloplasty	**Interventions for Valvular Disease and Heart Failure**	Other valvular and structural	Level 3 Zone G
Euro16A-POS0688	Dr GARCIA Daniel	Transcatheter tricuspid valve replacement: analysis of outcomes from all reported cases	**Interventions for Valvular Disease and Heart Failure**	Tricuspid/ Pulmonary valve	Level 3 Zone G
Euro16A-POS0701	Dr NEYLON Antoinette	Unprotected left main stenting in patients with severe aortic stenosis	**Interventions for Valvular Disease and Heart Failure/ Coronary intervention**	Left main disease	Level 3 Zone G
Euro16A-POS0712	Dr Dries-Devlin Jessica	Four-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expanding bioprosthesis	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0717	Dr Fiorina Claudia	Transaxillary vs. transaortic approach for TAVI with CoreValve Revalving System: insights from multicentre experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0722	Dr NAVIA Jose Luis	Novel catheter-guided tricuspid valved stent for secondary tricuspid regurgitation: concept verification in chronic animal studies	**Interventions for Valvular Disease and Heart Failure**	Tricuspid/ Pulmonary valve	Level 3 Zone G
Euro16A-POS0758	Dr Fateh-Moghadam Suzanne	Ad-hoc use of percutaneous transluminal angioplasty of the aorto-iliofemoral arteries for access preparation in complex transfemoral aortic valve implantation	**Interventions for Valvular Disease and Heart Failure**	Iliac/ femoral/ popliteal	Level 3 Zone G
Euro16A-POS0804	Dr Seidler Tim	Incidence and outcome of interventional treatment following access site complications in transfemoral aortic valve implantation	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0811	Dr Cockburn James	Poor mobilty predicts adverse outcome better than other frailty indices in patients udergoing TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0814	Dr Spaziano Marco	Mortality trends in low-, intermediate- and high-risk patients undergoing TAVI: real-world experience from a single high-volume centre	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F

Euro16A-POS0817	Dr Kebernik Julia	Comparison of outcomes between patients treated with antiplatelet therapy versus oral anticoagulation after TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0820	Dr NEYLON Antoinette	Transcatheter aortic valve replacement under local anaesthesia: why wouldn't you?	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0829	Dr Kebernik Julia	Impact of preprocedural percutaneous coronary revascularisation on outcomes after TAVI	**Interventions for Valvular Disease and Heart Failure/ Coronary intervention**	Stable CAD/ TAVI	Level 3 Zone G
Euro16A-POS0836	Dr Fuku Yasushi	Impact of small left ventricular size during or after balloon-expandable TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0854	Dr ROY Andrew	The effect of staged PCI followed by TAVI on periprocedural events and long-term mortality outcomes: results from a five-year TAVI registry study	**Interventions for Valvular Disease and Heart Failure/ Coronary intervention**	Stable CAD/ TAVI	Level 3 Zone G
Euro16A-POS0855	Mrs Kozaryn Radoslaw	Single-centre experience with the novel self-expanding NVT Allegra transcatheter aortic valve prosthesis	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0859	Mr Midha Prem	Optimisation of transcatheter valve-in-valve therapy: an in vitro haemodynamic evaluation	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0872	Dr Chandrasekhar Jaya	Gender based differences in 30-day outcomes with contemporary transcatheter aortic valve replacement: results from the BRAVO 3 randomised trial	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0889	Dr Guerrini Marco	Real-world increased procedural success of Lotus transcatheter aortic bioprosthesis system compared to CoreValve revalving system in an unselected population	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0895	Mr ARDOUIN Pierre	Cardiac CT before percutaneous ASD closure: comparison with stretched diameter and echocardiography	**Interventions for Valvular Disease and Heart Failure**	ASD/ PFO closure	Level 3 Zone G
Euro16A-POS0899	Mr Matheus Simonato	Mortality prediction after transcatheter treatment of failed bioprosthetic valves: insights from the Valve-in-Valve International Data registry (VIVID)	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0918	Dr Tateishi Hiroki	Videodensitometric quantification of aortic regurgitation after TAVI: results from the Brazilian TAVI Registry	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0940	Dr Komlev Alexey	Current trends in TAVI in Russia	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0956	Dr OSullivan Crochan	Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0972	Dr Regazzoli Damiano	LAA closure: a single-centre experience and comparison of two contemporary devices	**Interventions for Valvular Disease and Heart Failure**	LAA closure	Level 3 Zone G
Euro16A-POS0973	Dr Mangieri Antonio	Single vs. double antiplatelet therapy following TAVI: a single-centre experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS0974	Dr Abdul-Jawad Altisent Omar	Predictors and clinical impact of lack of exercise capacity improvement following transcatheter aortic valve replacement	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F

Euro16A-POS0980	Dr Ondrus Tomas	Minimally invasive mitral valve repair for functional mitral regurgitation in severe heart failure: catheter-based versus minimally invasive surgical approach	**Interventions for Valvular Disease and Heart Failure**	Mitral valve replacement and repair	Level 3 Zone F
Euro16A-POS0984	Dr Jabbar Avais	Local vs. general anaesthesia in TAVI: a tertiary centre experience	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1000	Dr Maisano Francesco	Transcatheter tricuspid reconstruction with a sutureless and adjustable device: initial preclinical validation	**Interventions for Valvular Disease and Heart Failure**	Tricuspid/ Pulmonary valve	Level 3 Zone G
Euro16A-POS1004	Dr Jabbar Avais	TAVI: a comparison of new generation valves	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1006	Dr Lavda Maria	DAPT after TAVI and five-year all cause mortality	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1016	Dr Ahmed Walid	Temporal changes of left ventricular synchronisation parameters and long-term outcomes of cardiac resynchronisation therapy	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS1025	Dr Ahmed Walid	Evaluation of ventricular scar burden for outcomes of cardiac resynchronisation therapy, evaluated by cardiac MRI and gated single-photon emission computerized tomography (SPECT)	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS1029	Dr Ahmed Walid	Evaluation of ventricular dyssynchrony and scar burden for outcomes of cardiac resynchronisation therapy	**Interventions for Valvular Disease and Heart Failure**	Chronic heart failure	Level 3 Zone F
Euro16A-POS1032	Dr Carmo João	Baseline albumin predicts long-term mortality in patients undergoing TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1051	Dr ROY Andrew	In-hospital and long-term outcomes of balloon aortic valvuloplasty as a bridge to TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1055	Dr Spaziano Marco	TAVI vs. re-do surgery for failing surgical aortic bioprosthesis: a multicentre comparison of post-procedural gradients	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1059	Dr ALBARRAN Agustin	Rupture of the device landing zone during TAVI: is it really such a rare complication?	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1080	Dr Carmo João	Performance of score FRANCE 2 for evaluation of early mortality in patients undergoing TAVI	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1081	Dr Vale Nelson	Long-term outcomes of transfemoral and transapical TAVI after propensity matching	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1088	Dr Grubb Kendra	Improved outcomes in transcatheter aortic valve replacement using a minimalist approach	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1092	Dr Pinto-Teixeira Pedro	Percutaneous closure of paravalvular leaks: reasonable alternative to high-risk surgery	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F
Euro16A-POS1104	Dr BOUKANTAR Madjid	Coronary procedures in patients treated by TAVI with self-expanding aortic bioprosthesis, not an easy matter	**Interventions for Valvular Disease and Heart Failure**	TAVI	Level 3 Zone F

Euro16A-POS0034	Dr Roussanov Oleg	Intra-arterial thrombolysis for subacute lower limb ischaemia	**Peripheral Interventions**	Below the knee	Level 2 Zone C
Euro16A-POS0179	Dr Yamamoto Mitsutaka	Potential of fluorescence navigation with injection of indocyanine green (ICG) in critical limb ischemia (CLI)	**Peripheral Interventions**	Below the knee	Level 2 Zone C
Euro16A-POS0181	Dr Cho Sang Cheol	Early versus late thrombolysis in acute arterial occlusion	**Peripheral Interventions**	Below the knee	Level 2 Zone C
Euro16A-POS0313	Dr Choi Jong Hyun	Endovascular treatment of ruptured thoracic aortic disease: a single-centre experience	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS0343	Dr Kim Bo Won	Endovascular treatment in patients with complicated type B aortic dissection and mal-perfusion syndrome: long-term results from single centre	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS0568	Dr VURUSKAN Ertan	Procedural and early outcomes of two different reentrey devices for subintimal recanalisation of artoiliac and femoropopliteal CTO	**Peripheral Interventions**	Iliac/ femoral/ popliteal	Level 2 Zone C
Euro16A-POS0721	Prof CHOI Seongil	Association between anatomy of coronary artery stenotic lesions and renal artery stenosis in patients undergoing simultaneous coronary and renal angiography	**Peripheral Interventions/ Coronary interventions**	Stable CAD	Level 2 Zone C
Euro16A-POS0824	Dr Stefanov Florian	Primary versus secondary intervention evaluation for twelve aortic type B dissections managed with the streamliner	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS0878	Mr Shiratori Yoshitaka	Three-year clinical outcome after angioplasty for symptomatic lower-limb ischaemia in haemodialysis patients	**Peripheral Interventions**	Below the knee	Level 2 Zone C
Euro16A-POS0927	Dr Blachut Aleksandra	Vascular closure device for closure after antegrade femoral puncture in peripheral endovascular interventions	**Peripheral Interventions**	Iliac/ femoral/ popliteal	Level 2 Zone C
Euro16A-POS0999	Dr Mayordomo Gómez Sandra	IVUS guidance for percutaneous treatment of aortic coarctation	**Peripheral Interventions**	Other peripheral intervention	Level 2 Zone C
Euro16A-POS1010	Dr Janas Adam	Long-term outcomes after revascularisation of long superficial femoral artery occlusions with OCT-guided atherectomy Ocelot catheter: results from the pivotal first-in-man study	**Peripheral Interventions**	Iliac/ femoral/ popliteal	Level 2 Zone C
Euro16A-POS1021	Dr Janas Adam	Long-term outcomes in diabetic patients treated with atherectomy for peripheral artery disease	**Peripheral Interventions**	Iliac/ femoral/ popliteal	Level 2 Zone C
Euro16A-POS1034	Dr Hong Sung-Jin	The predictors of all-cause of mortality in the patients undergoing lower extremity endovascular intervention: the effect of obesity paradox	**Peripheral Interventions**	Below the knee	Level 2 Zone C